NPI: 1700860491 · MORGANTON, NC 28655 · General Acute Care Hospital · NPI assigned 12/06/2005
Authorized official MOLL, PATRICIA controls 20+ related entities in our dataset. Read more
| Authorized Official | MOLL, PATRICIA (CHIEF FINANCIAL OFFICER) |
| NPI Enumeration Date | 12/06/2005 |
Other providers sharing the same authorized official: MOLL, PATRICIA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 46,281 | $1.87M |
| 2019 | 50,613 | $2.20M |
| 2020 | 34,031 | $1.54M |
| 2021 | 45,216 | $2.75M |
| 2022 | 64,801 | $3.56M |
| 2023 | 72,595 | $3.94M |
| 2024 | 78,146 | $4.27M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 36,798 | 34,102 | $6.11M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 29,160 | 26,624 | $5.73M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9,152 | 8,352 | $1.88M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 9,201 | 8,314 | $1.45M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 23,111 | 19,313 | $677K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 813 | 751 | $460K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6,202 | 5,815 | $442K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 12,826 | 11,664 | $321K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 37,352 | 32,766 | $279K |
| 80053 | Comprehensive metabolic panel | 32,328 | 28,559 | $277K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 7,947 | 7,095 | $244K |
| 96375 | Therapeutic injection; each additional sequential IV push | 6,490 | 5,606 | $232K |
| 62323 | 1,050 | 809 | $185K | |
| 41899 | Unlisted procedure, dentoalveolar structures | 108 | 106 | $178K |
| J3490 | Unclassified drugs | 63,932 | 31,018 | $166K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4,492 | 3,914 | $107K |
| 71045 | Radiologic examination, chest; single view | 4,036 | 3,701 | $104K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1,061 | 588 | $74K |
| 20610 | 799 | 515 | $64K | |
| 81001 | 17,981 | 16,367 | $60K | |
| 71046 | Radiologic examination, chest; 2 views | 2,071 | 1,913 | $60K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,538 | 1,416 | $57K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 845 | 774 | $57K |
| 87400 | 4,816 | 2,854 | $53K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2,283 | 2,039 | $51K |
| 70450 | Computed tomography, head or brain; without contrast material | 322 | 260 | $48K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3,567 | 3,146 | $47K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 163 | 154 | $45K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 677 | 629 | $45K |
| 81025 | 4,329 | 3,981 | $36K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 472 | 299 | $34K |
| 83690 | 4,664 | 4,107 | $33K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1,912 | 1,810 | $30K |
| G0378 | Hospital observation service, per hour | 276 | 220 | $27K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 794 | 711 | $27K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 574 | 349 | $25K |
| 84484 | 2,842 | 2,404 | $24K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 2,835 | 2,553 | $22K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 263 | 241 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 48 | 43 | $22K |
| 20553 | 163 | 159 | $17K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 57 | 50 | $16K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2,350 | 1,882 | $15K |
| 83605 | 1,084 | 974 | $14K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 111 | 94 | $13K |
| 80061 | Lipid panel | 863 | 827 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,711 | 1,555 | $12K |
| 83735 | 1,957 | 1,739 | $12K | |
| 59025 | Fetal non-stress test | 145 | 126 | $11K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 4,197 | 3,735 | $11K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 166 | 157 | $11K |
| 62321 | 27 | 25 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 346 | 327 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,071 | 1,008 | $9K |
| 87081 | 914 | 889 | $9K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 1,321 | 1,137 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | 767 | 732 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 393 | 366 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2,921 | 2,702 | $8K |
| 27096 | 133 | 60 | $8K | |
| 74018 | 186 | 179 | $7K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 1,871 | 1,639 | $7K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 2,390 | 1,740 | $6K |
| 81003 | 1,295 | 1,198 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | 976 | 495 | $5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 2,769 | 2,230 | $5K |
| 36415 | Collection of venous blood by venipuncture | 2,090 | 1,654 | $5K |
| J2704 | Injection, propofol, 10 mg | 1,858 | 1,615 | $5K |
| 72141 | 30 | 29 | $5K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 1,942 | 1,478 | $5K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 2,453 | 2,214 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | 200 | 196 | $4K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 1,861 | 962 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 97 | 87 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,099 | 1,025 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 219 | 180 | $3K |
| 87420 | 169 | 167 | $2K | |
| 97597 | 41 | 25 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 746 | 668 | $2K |
| 85027 | 309 | 276 | $2K | |
| 77336 | 25 | 12 | $1K | |
| 96415 | 38 | 24 | $1K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 13 | 12 | $1K |
| 85610 | 364 | 342 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 1,261 | 1,157 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | 671 | 571 | $1K |
| 80320 | 80 | 75 | $1K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 294 | 258 | $1K |
| J8597 | Antiemetic drug, oral, not otherwise specified | 226 | 215 | $1K |
| 83880 | 38 | 36 | $951.48 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 394 | 311 | $913.14 |
| 76942 | 13 | 13 | $893.09 | |
| 82962 | 681 | 589 | $885.01 | |
| 80329 | 15 | 14 | $761.33 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 128 | 118 | $743.62 |
| 87040 | 30 | 29 | $606.77 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 168 | 145 | $566.43 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 200 | 183 | $549.62 |
| 71271 | 13 | 12 | $453.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 69 | 63 | $400.89 |
| 81015 | 81 | 80 | $395.29 | |
| 82728 | 27 | 26 | $365.73 | |
| 96376 | 16 | 12 | $331.86 | |
| Q3014 | Telehealth originating site facility fee | 38 | 30 | $315.29 |
| 94760 | 246 | 123 | $298.47 | |
| G0238 | Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring) | 15 | 15 | $254.98 |
| 90715 | 19 | 15 | $243.51 | |
| 83550 | 26 | 25 | $234.69 | |
| 83540 | 26 | 25 | $174.17 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 19 | 15 | $158.67 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 84 | 83 | $158.20 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 157 | 141 | $148.93 |
| 82550 | 18 | 18 | $145.73 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 69 | 65 | $128.93 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 15 | 14 | $125.57 |
| 84439 | 12 | 12 | $107.69 | |
| 85730 | 16 | 14 | $66.57 | |
| 82948 | 38 | 34 | $65.31 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 82 | 77 | $57.28 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 15 | 13 | $54.80 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 27 | 25 | $46.58 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 14 | 14 | $44.80 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 13 | 13 | $43.27 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 241 | 97 | $38.13 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 12 | 12 | $34.87 |
| J2060 | Injection, lorazepam, 2 mg | 12 | 12 | $31.83 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 16 | 13 | $30.50 |
| J1171 | Injection, hydromorphone, 0.1 mg | 14 | 12 | $22.98 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 28 | 27 | $17.73 |
| 85018 | 23 | 18 | $5.90 | |
| A9270 | Non-covered item or service | 1,417 | 556 | $1.75 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 430 | 304 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 268 | 156 | $0.00 |